Skip to main content

Table 1 Baseline characteristics of the 72 included rheumatoid arthritis patients

From: Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies

 

All RA patients ( n= 72)

Anti-CII-negative RA patients ( n= 48)

Anti-CII-positive (>29 AU/ml) RA patients ( n= 24)

P (between anti-CII-negative and all anti-CII-positive patients)

Anti-CII highly positive (>470 AU/ml) RA patients ( n= 9)

P (between anti-CII-negative and highly anti-CII-positive patients)

Mean age at onset (years)

59.6 (14.4)

59.7 (15.0)

59.4 (30.5)

NS

63.3 (13.7)

NS

% females

76 (55/72)

79.2 (38/48)

70.8 (17/24)

NS

66.7 (6/9)

NS

Mean disease duration at inclusion (months)

5.5 (2.6)

6.1 (2.8)

4.2 (1.6)

0.005

4.4 (1.4)

NS (0.08)

RF-positive (%; number positive/total number)

51 (36/71)

50 (24/48)

52 (12/23)

NS

44 (4/9)

NS

Anti-CCP2-positive, (%; number positive/total number)

47 34/72

48 (23/48)

37.5 (9/24)

NS

33.3 (3/9)

NS

CRP (mg/l)

31 (40)

20 (18)

53 (60)

0.020

46 (34)

0.007

ESR (mm/hour)

28 (22)

24 (18)

36 (27)

NS

41 (27)

0.039

Physician’s assessment of disease activity (0 to 4)

2.1 (0.8)

2.0 (0.8)

2.3 (0.6)

NS

2.4 (0.5)

NS

Number of swollen joints

10 (5)

8 (5)

12 (6)

0.022

10 (5)

NS

Number of tender joints

9 (5)

9 (5)

8 (6)

NS

8 (3)

NS

DAS28

5.1 (1.1)

5.0 (1.0)

5.2 (1.3)

NS

5.5 (0.9)

NS

Global VAS

43 (27)

45 (27)

39 (28)

NS

46 (29)

NS

Pain VAS

45 (23)

49 (23)

38 (21)

NS

37 (21)

NS

HAQ

0.99 (0.59)

0.97 (0.58)

1.02 (0.61)

NS

1.33 (0.55)

NS

Baseline Larsen score

9.71 (10.42)

9.36 (10.69)

10.37 (10.05)

NS

12.28 (6.52)

NS (0.12)

% of patients starting DMARD therapy at baseline

92 (66/72)

96 (46/48)

83 (20/24)

NS

89 (8/9)

NS

  1. Data presented as means values (standard deviation) and as percentages (ratios). Differences between anti-CII-negative and anti-CII-positive patients are analyzed using Mann–Whitney’s U test, whereas differences between proportions are analyzed using the chi-square test or Fisher’s exact test when appropriate. Data for anti-CCP and RF have been published earlier [35,36]. Data for RF at the time of diagnosis are missing for one patient. Significant values are in bold. We have deliberately expressed mean values to allow comparison with previously published data on the full RA cohort ([3]; n = 274). anti-CCP2, cyclic citrullinated peptide version 2 antibodies; anti-CII, collagen type II autoantibodies; AU, arbitrary units; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; NS, nonsignificant; RA, rheumatoid arthritis; RF, rheumatoid factor; VAS, visual analog scale.